Physician profile
Michael A Berk
NPI 1700802014
$28,663.97
in general payments reported to CMS, 2019-2025
31 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $608 · 2021: $2,756 · 2022: $726 · 2023: $863 · 2024: $1,345 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,733.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $24,335.43 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Medtronic, INC. | $1,689.93 | 2021-2023 | Intellis Adaptivestim |
| Lilly USA, LLC | $544.81 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $354.05 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $228.99 | 2021-2025 | Repatha, Repatha |
| Abbvie INC. | $224.37 | 2021-2023 | Vraylar |
| Dexcom, INC. | $163.59 | 2023-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $159.72 | 2021-2025 | Rybelsus, Ozempic |
| W. L. Gore & Associates, INC. | $135.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $112.48 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $91.57 | 2024 | |
| Astellas Pharma US INC | $81.88 | 2021 | |
| Radius Health, INC. | $68.78 | 2024-2025 | Tymlos |
| Allergan, INC. | $62.97 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.87 | 2020-2025 | Jardiance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clarus Therapeutics INC. | $47.81 | 2021 | |
| Antares Pharma, INC. | $43.12 | 2020-2021 | |
| Glaxosmithkline, LLC. | $33.80 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $31.45 | 2023 | |
| Recor Medical INC | $30.76 | 2024 | Paradise Renal Denervation System |
| E.R. Squibb & Sons, L.L.C. | $20.82 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $17.33 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $16.96 | 2021 | |
| Lifescan, INC. | $16.88 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.86 | 2021 | |
| Beta Bionics, INC. | $15.58 | 2024 | Ilet Bionic Pancreas |
| Phathom Pharmaceuticals, INC. | $14.74 | 2024 | Voquezna |
| Amarin Pharma, INC. | $14.31 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.00 | 2024 | Horizant |
| Merck Sharp & Dohme LLC | $12.66 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Berk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.